Literature DB >> 30190852

Management of melanoma brain metastases.

Mary Frances McAleer1,1, Dae W Kim2,2, Van A Trinh3,3, Wen-Jen Hwu2,2.   

Abstract

Relapses in the brain remain a major obstacle to cure in many patients with advanced melanoma. At present, the management of melanoma brain metastases continues to rely heavily on surgical and radiotherapeutic interventions, which have become safer and more effective with modern imaging, surgery and radiation technologies. Additionally, novel targeted and immunotherapeutic agents, shown to generate meaningful intracranial response and survival benefit in patients with melanoma brain metastases when compared with historical controls, expand systemic treatment options for this subset of patients. These systemic therapies become particularly important when intracranial disease burden precludes neuro- or radio-surgery. Considerable multidisciplinary research effort is ongoing to improve outcomes for melanoma patients with brain metastases, a key challenge in the management of advanced melanoma.

Entities:  

Keywords:  advanced melanoma; brain metastases; immunotherapy; neurosurgery; radiation therapy; systemic therapy; targeted therapy

Year:  2015        PMID: 30190852      PMCID: PMC6094653          DOI: 10.2217/mmt.15.16

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  80 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

3.  Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.

Authors:  C Jacquillat; D Khayat; P Banzet; M Weil; M F Avril; P Fumoleau; M Namer; J Bonneterre; P Kerbrat; J J Bonerandi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

5.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

6.  Melanoma's deadly march to the brain: by what route, and can it be stopped?

Authors:  Megan Othus; James Moon; Kim Margolin
Journal:  Cancer       Date:  2010-11-10       Impact factor: 6.921

7.  Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Authors:  Reinhard Dummer; Simone M Goldinger; Christian P Turtschi; Nina B Eggmann; Olivier Michielin; Lada Mitchell; Luisa Veronese; Paul René Hilfiker; Lea Felderer; Jeannine D Rinderknecht
Journal:  Eur J Cancer       Date:  2013-11-29       Impact factor: 9.162

8.  Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.

Authors:  Amanda D Bucheit; Guo Chen; Alan Siroy; Michael Tetzlaff; Russell Broaddus; Denai Milton; Patricia Fox; Roland Bassett; Patrick Hwu; Jeffrey E Gershenwald; Alexander J Lazar; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-08-27       Impact factor: 12.531

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

Authors:  M F Avril; S Aamdal; J J Grob; A Hauschild; P Mohr; J J Bonerandi; M Weichenthal; K Neuber; T Bieber; K Gilde; V Guillem Porta; J Fra; J Bonneterre; P Saïag; D Kamanabrou; H Pehamberger; J Sufliarsky; J L Gonzalez Larriba; A Scherrer; Y Menu
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.